Following the launch of its urine-based Qsant assay later this year, the firm plans to develop updated versions of it with new biomarkers for different disease indications.
The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.
VolitionRx, which develops epigenetic-based blood tests for cancer and other diseases, said it will use the proceeds of the offering for general corporate purposes.
